Browsing: generics

Building on three years of generic adherence experience, Sempre brings its proven engagement model to the full medication portfolio of members already enrolled through their branded therapy

The Indian GLP-1 agonist market has grown into a Rs 2,055 crore segment as of the moving annual total (MAT) ending June 2026, driven by rapid adoption of newer therapies for diabetes and obesity. However, after two years of exceptional expansion, the market is showing early signs of stabilisation as the pace of growth moderates,…